Jazz Pharmaceuticals JAZZ Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's change in AR?
- Jazz Pharmaceuticals (JAZZ) reported change in AR of $6.5M in Q1 2026.
- How has Jazz Pharmaceuticals's change in AR changed year-over-year?
- Jazz Pharmaceuticals's change in AR increased by 109.8% year-over-year, from -$66M to $6.5M.
- What is the long-term trend for Jazz Pharmaceuticals's change in AR?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's change in AR has grown at a 1.6% compound annual growth rate (CAGR), from $99.62M to $106.28M.
- What does change in AR mean?
- The change in the amount of money owed to the company by its customers.
- How do you interpret change in AR?
- An increase in accounts receivable is a use of cash, while a decrease is a source of cash.
- How does change in AR compare across companies?
- Standard across all industries; peers with shorter payment terms typically show lower relative balances.